Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

EOLS

Evolus Inc

Dec 04 • 04:00PM ET

12.96

Dollar change -0.14
Percentage change -1.07	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Peers: ABBV LLY PFE AMGN BMY RVNC MRK TEVA PRGO PRPH

| Held by: VTI IWM VXF IWO VTWO SCHA VHT IWC PTH XPH

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.91	Insider Own	13.69%	Shs Outstand	63.25M	Perf Week	1.01%
Market Cap	820.65M	Forward P/E	-	EPS next Y	-0.03	Insider Trans	-5.33%	Shs Float	54.65M	Perf Month	-21.07%
Income	-55.46M	PEG	-	EPS next Q	0.02	Inst Own	79.72%	Short Float	9.68%	Perf Quarter	-13.48%
Sales	248.33M	P/S	3.30	EPS this Y	63.89%	Inst Trans	-2.29%	Short Ratio	8.24	Perf Half Y	-0.31%
Book/sh	0.09	P/B	139.18	EPS next Y	87.99%	ROA	-27.90%	Short Interest	5.29M	Perf Year	30.98%
Cash/sh	1.34	P/C	9.65	EPS next 5Y	16.50%	ROE	-861.68%	52W Range	9.38 - 17.82	Perf YTD	23.08%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.81%	ROI	-41.34%	52W High	-27.27%	Beta	1.29
Dividend TTM	-	Quick Ratio	2.23	Sales past 5Y	44.65%	Gross Margin	67.81%	52W Low	38.17%	ATR (14)	0.68
Dividend Ex-Date	-	Current Ratio	2.47	EPS Y/Y TTM	17.75%	Oper. Margin	-12.71%	RSI (14)	41.26	Volatility	5.05% 5.34%
Employees	273	Debt/Eq	22.05	Sales Y/Y TTM	34.43%	Profit Margin	-22.33%	Recom	1.14	Target Price	23.43
Option/Short	Yes / Yes	LT Debt/Eq	21.78	EPS Q/Q	-2.29%	Payout	-	Rel Volume	0.90	Prev Close	13.10
Sales Surprise	-3.31%	EPS Surprise	-31.14%	Sales Q/Q	22.12%	Earnings	Nov 06 AMC	Avg Volume	642.23K	Price	12.96
SMA20	-0.99%	SMA50	-14.47%	SMA200	-5.50%	Trades		Volume	572,105	Change	-1.07%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Upgrade	Barclays	Equal Weight → Overweight	$10 → $16
Jun-23-22	Initiated	Needham	Buy	$18
May-12-22	Upgrade	Barclays	Underweight → Equal Weight	$8 → $10
Jan-20-22	Upgrade	Truist	Hold → Buy	$11
May-06-21	Upgrade	Mizuho	Neutral → Buy	$15
Apr-08-21	Reiterated	H.C. Wainwright	Buy	$20 → $22
Feb-24-21	Downgrade	Truist	Buy → Hold	$12
Jul-07-20	Downgrade	Mizuho	Buy → Neutral	$8 → $3
Feb-06-20	Resumed	Mizuho	Buy
Nov-26-19	Initiated	SVB Leerink	Outperform	$25
Sep-05-19	Resumed	Mizuho	Buy	$30
Jun-28-19	Initiated	Wells Fargo	Market Perform	$16
Jun-11-19	Initiated	Barclays	Underweight	$13
Mar-20-19	Initiated	SunTrust	Buy	$30
Feb-14-19	Initiated	H.C. Wainwright	Buy	$37
Jan-29-19	Initiated	Stifel	Buy	$27

Show Previous Ratings

Nov-18-24 09:55AM	Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher (Zacks)
Nov-14-24 09:35AM	Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS) (Zacks)
Nov-07-24 06:00AM	Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges (GuruFocus.com) -14.99%
Nov-06-24 06:25PM	Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Evolus Reports Third Quarter 2024 Results (Business Wire)
08:00AM	Loading…
Nov-01-24 08:00AM	Evolus to Participate in Stifel 2024 Healthcare Conference (Business Wire)
Oct-31-24 02:02PM	Evolus Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation (Business Wire)
Oct-30-24 10:01AM	Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-29-24 08:00AM	Evolus Rewards Patient Loyalty Program Surpasses 1 Million Enrolled Consumers (Business Wire)
Oct-23-24 08:00AM	Evolus to Report Third Quarter Financial Results on November 6, 2024 (Business Wire)
Oct-11-24 10:53PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-09-24 03:36PM	Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
Sep-27-24 09:00PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-06-24 08:00AM	Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024 (Business Wire)
Aug-09-24 04:30PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:39AM	Loading…
07:39AM	Evolus, Inc. (EOLS): Is It One of Caligan Partners Top Holdings Now? (Insider Monkey)
Aug-01-24 04:00PM	Evolus, A Medical Aesthetics Player, Becomes Profitable Two Quarters Early (Investor's Business Daily) +13.04%
Jul-31-24 09:56PM	EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace)
06:45PM	Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance (Business Wire)
08:00AM	Evolus to Hold Investor Day on September 12, 2024 (Business Wire)
Jul-30-24 08:00AM	Evolus Expands Global Footprint with Introduction of Nuceiva (botulinum toxin type A) in Australia (Business Wire)
Jul-25-24 08:00AM	Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire)
Jul-23-24 07:03AM	Evoluss frown line treatment Jeuveau could threaten Botox revenues (Pharmaceutical Technology)
Jul-17-24 08:00AM	Evolus to Report Second Quarter Financial Results on July 31, 2024 (Business Wire)
Jul-01-24 08:00AM	Evolus Announces Appointment of Albert G. White III to Board of Directors (Business Wire)
Jun-24-24 08:00AM	Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse Dermal Filler Products (Business Wire)
Jun-12-24 08:00AM	Evolus Broadens International Presence with Launch of Nuceiva (botulinum toxin type A) in Spain (Business Wire)
Jun-07-24 05:00PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.73%
May-28-24 01:00AM	The Evolution of Medical Aesthetics and Its Growing Foothold in the Beauty Space (WWD)
10:57AM	Loading…
May-21-24 10:57AM	Evolus (EOLS) Releases Favorable Dermal Fillers Study Data (Zacks)
May-20-24 08:30AM	Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse Dermal Filler Products at 2024 SCALE Meeting (Business Wire)
May-16-24 02:54AM	Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS) (GuruFocus.com)
02:54AM	Director Vikram Malik Sells 28,000 Shares of Evolus Inc (EOLS) (GuruFocus.com)
May-15-24 08:30AM	Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau at the Women's Wear Daily Beauty CEO Summit (Business Wire)
May-10-24 06:55PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:10AM	Evolus Sandra Beaver Named Orange County Business Journals Public Company CFO of the Year (Business Wire)
May-08-24 11:09AM	Evolus, Inc. (NASDAQ:EOLS) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:24AM	Q1 2024 Evolus Inc Earnings Call (Thomson Reuters StreetEvents)
03:53AM	Evolus Inc (EOLS) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth and Strategic ... (GuruFocus.com)
May-07-24 08:58PM	EOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:35PM	Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:46PM	Evolus Inc (EOLS) Q1 2024 Earnings: Surpasses Revenue Estimates with Significant Growth (GuruFocus.com)
04:05PM	Evolus Reports First Quarter 2024 Results and Provides Business Update (Business Wire)
May-02-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Apr-23-24 04:30PM	Evolus to Report First Quarter Financial Results on May 7, 2024 (Business Wire)
Apr-21-24 10:39AM	11 Best Low Price Pharma Stocks To Invest In (Insider Monkey)
Apr-17-24 04:05PM	Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for Extra-Strength 40U Formulation of Jeuveau (Business Wire)
Apr-12-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-26-24 08:00AM	Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-14-24 07:04AM	10 Stocks George Soros and Insiders Are Crazy About (Insider Monkey)
Mar-13-24 09:55AM	Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect? (Zacks)
Mar-11-24 07:00AM	Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock (Business Wire)
Mar-08-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
03:24PM	Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:30PM	Q4 2023 Evolus Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-24 10:34PM	Evolus Inc (EOLS) Reports Record Revenues in Q4 and Full Year 2023, Eyes Profitability in 2024 (GuruFocus.com)
09:53PM	EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:05PM	Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance (Business Wire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Mar-01-24 08:30AM	Evolus Announces Results from European Head-to-Head Filler Trial (Business Wire)
Feb-27-24 08:30AM	Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences (Business Wire)
Feb-22-24 04:30PM	Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024 (Business Wire)
Feb-09-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-02-24 09:10PM	Evolus Inc Director Karah Parschauer Sells 11,931 Shares (GuruFocus.com) -5.20%
Jan-16-24 05:28PM	Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance (Business Wire) +19.65%
Jan-12-24 04:23PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-09-24 06:21PM	Wall Street Analysts See a 133.85% Upside in Evolus, Inc. (EOLS): Can the Stock Really Move This High? (Zacks)
Jan-04-24 04:05PM	Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications (Business Wire)
Dec-20-23 08:00AM	Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe (Business Wire)
Dec-08-23 04:30PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-13-23 09:08AM	Evolus, Inc. (NASDAQ:EOLS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 05:16PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-23 04:16PM	Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau (Business Wire) +8.17%
Nov-06-23 08:45AM	Extra-Strength 40U Formulation of JeuveauDemonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting (Business Wire)
Nov-01-23 08:45AM	Evolus to Participate in November Investor Conferences (Business Wire)
Oct-25-23 08:45AM	Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting (Business Wire)
08:45AM	Evolus to Report Third Quarter 2023 Results (Business Wire)
Oct-08-23 06:41PM	7 Must-Own Small-Cap Stocks That Could Outperform the Market (InvestorPlace)
Sep-29-23 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.14%
Sep-13-23 04:10PM	7 Small-Cap Stocks Analysts Predict Will Double in 2024 (InvestorPlace)
Sep-09-23 01:03PM	Insider Sell: CFO Sandra Beaver Sells 3,178 Shares of Evolus Inc (EOLS) (GuruFocus.com)
Sep-03-23 05:29AM	12 Cheapest and Best Countries for Plastic Surgery (Insider Monkey)
Aug-29-23 08:45AM	Evolus to Participate in September Conferences (Business Wire)
Aug-27-23 07:20PM	Insiders Pour Millions Into These 2 Stocks, Analysts Say They Have up to 120% Upside Heres Why You Should Pay Attention (TipRanks)
Aug-23-23 06:53PM	Evolus Announces Inducement Grants for New Chief Marketing Officer (Business Wire)
Aug-21-23 08:45AM	Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer (Business Wire)
Aug-08-23 09:15AM	Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline (Newsfile)
08:45AM	Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers (Business Wire)
Aug-02-23 05:45PM	Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Evolus Reports Second Quarter 2023 Results and Provides Business Update (Business Wire)
Jul-27-23 11:42AM	Why Shares of Evolus Are Jumping Thursday (Motley Fool) +29.54%
08:45AM	Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue (Business Wire)
Jul-26-23 10:02AM	Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know (Zacks)
08:45AM	Evolus to Participate in Canaccord Genuitys 43rd Annual Growth Conference (Business Wire)
Jul-19-23 08:45AM	Evolus to Report Second Quarter 2023 Results and Provide Business Update (Business Wire)
Jul-15-23 07:30AM	Twitter Faces Threats From AI and Threads (Motley Fool)
Jun-29-23 09:00AM	Evolus Launches Nuceiva® (botulinum toxin type A) in Italy (Business Wire)
Jun-22-23 08:45AM	Evolus Announces Successful Completion of Phase 2 Study Evaluating "Extra-Strength" Dose of Jeuveau ® (Business Wire)
Jun-08-23 04:05PM	Evolus Reaches 1 Million Redemptions in its Evolus Rewards Patient Loyalty Program (Business Wire)

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Beaver Sandra	Chief Financial Officer	Sep 06 '24	Sale	14.98	3,276	49,074	148,502	Sep 06 09:45 PM
Yamagishi-Dressler Tomoko	Chief Marketing Officer	Aug 30 '24	Sale	15.85	5,631	89,251	82,375	Sep 04 04:14 PM
MOATAZEDI DAVID	See Remarks	Jun 06 '24	Option Exercise	7.28	175,940	1,280,843	709,289	Jun 06 07:01 PM
MOATAZEDI DAVID	See Remarks	Jun 05 '24	Option Exercise	5.46	155,278	847,818	688,627	Jun 06 07:01 PM
MOATAZEDI DAVID	See Remarks	Jun 06 '24	Sale	12.59	175,940	2,214,486	533,349	Jun 06 07:01 PM
MOATAZEDI DAVID	See Remarks	Jun 05 '24	Sale	12.92	155,278	2,006,456	533,349	Jun 06 07:01 PM
MOATAZEDI DAVID	See Remarks	Jun 04 '24	Sale	12.73	140,214	1,784,686	533,349	Jun 06 07:01 PM
Malik Vikram	Director	Jun 03 '24	Sale	12.96	7,500	97,203	246,514	Jun 05 09:30 PM
GILL DAVID N	Director	May 14 '24	Sale	12.60	6,718	84,654	33,964	May 15 05:20 PM
GILL DAVID N	Director	May 13 '24	Sale	12.72	3,643	46,356	40,682	May 15 05:20 PM
Malik Vikram	Director	May 13 '24	Sale	12.93	28,000	362,012	254,014	May 15 05:19 PM
MOATAZEDI DAVID	See Remarks	May 10 '24	Sale	12.72	16,051	204,127	673,563	May 14 08:56 PM
Avelar Rui	See Remarks	May 10 '24	Sale	12.72	3,441	43,761	368,847	May 14 08:56 PM
Beaver Sandra	Chief Financial Officer	May 10 '24	Sale	12.72	2,423	30,814	151,778	May 14 08:55 PM
MOATAZEDI DAVID	See Remarks	Mar 27 '24	Sale	13.86	6,236	86,431	689,614	Mar 29 07:08 PM
Avelar Rui	See Remarks	Mar 19 '24	Sale	13.92	27,603	384,350	372,288	Mar 21 06:09 PM
Beaver Sandra	Chief Financial Officer	Mar 19 '24	Sale	13.92	5,672	78,978	154,201	Mar 21 06:09 PM
MOATAZEDI DAVID	See Remarks	Mar 19 '24	Sale	13.92	96,566	1,344,604	695,850	Mar 21 06:08 PM
MOATAZEDI DAVID	See Remarks	Feb 22 '24	Sale	13.08	7,706	100,804	792,416	Feb 23 08:27 PM
Avelar Rui	See Remarks	Feb 22 '24	Sale	13.08	1,821	23,821	399,891	Feb 23 08:27 PM
Beaver Sandra	Chief Financial Officer	Feb 22 '24	Sale	13.08	1,821	23,821	159,873	Feb 23 08:27 PM
Parschauer Karah Herdman	Director	Jan 30 '24	Sale	13.14	11,931	156,733	31,243	Feb 02 04:57 PM
MOATAZEDI DAVID	See Remarks	Dec 06 '23	Sale	10.09	51,348	517,891	635,244	Dec 08 06:15 PM
MOATAZEDI DAVID	See Remarks	Dec 08 '23	Sale	9.73	31,300	304,505	603,944	Dec 08 06:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EOLS

Evolus Inc

Upgrade your FINVIZ experience